{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:24:14Z","timestamp":1790429054164,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>A national organized cytology-based cervical cancer screening program was launched in 2018 and rollout is ongoing. Concomitantly, the High Authority for Health (HAS) recently assessed new evidence on primary HPV testing to update screening recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The HAS commissioned systematic reviews and meta-analyses to evaluate the effectiveness of primary HPV screening; accuracy of HPV testing on self-samples; effectiveness of self-sampling to reach underscreened women; and triage strategies to manage HPV-positive women. Recommendations developed by the HAS were reviewed by a multidisciplinary group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Compared with cytology screening, HPV screening is more sensitive to detect precancers but less specific. In women aged \u226530, if the test is negative, HPV screening greatly reduces the risk of developing precancer and cancer for at least 5 years. HPV testing, using validated PCR-based assays, is as sensitive and slightly less specific on self-samples than on clinician-taken samples. Self-sampling is more effective to reach underscreened women than sending invitations to have a specimen taken by a clinician. Two-time triage strategies ensure a sufficiently high risk if triage-positive to justify referral and low risk if triage-negative allowing release to routine screening.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The HAS recommends three-yearly cytology screening for women aged 25\u201329 and HPV screening for those aged 30\u201365 with an extension of the screening interval to 5 years if the HPV test is negative. Self-sampling should be offered to underscreened women aged \u226530. HPV-positive women should be triaged with cytology. Those with abnormal cytology should be referred for colposcopy and those with normal cytology re-tested for HPV 12 months later. Recommendations for implementation of HPV-based screening in the organized program are provided.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000701","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T19:55:01Z","timestamp":1625082901000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Updated evidence-based recommendations for cervical cancer screening in France"],"prefix":"10.1097","volume":"31","author":[{"given":"Fran\u00e7oise F.","family":"Hamers","sequence":"first","affiliation":[{"name":"National Public Health Agency (Sant\u00e9 publique France)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Isabelle","family":"Poulli\u00e9","sequence":"additional","affiliation":[{"name":"High Authority for Health (HAS), Saint-Denis La Plaine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Arbyn","sequence":"additional","affiliation":[{"name":"Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","article-title":"Trends of cervical cancer mortality in the member states of the European Union.","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur J Cancer"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdp471","article-title":"European guidelines for quality assurance in cervical cancer screening. Second edition\u2013summary document.","volume":"21","author":"Arbyn","year":"2010","journal-title":"Ann Oncol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/M15-2735","article-title":"Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis.","volume":"166","author":"Arbyn","year":"2017","journal-title":"Ann Intern Med"},{"issue":"Suppl 5","key":"R7-20250527","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","article-title":"Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.","volume":"15","author":"Arbyn","year":"2014","journal-title":"Lancet Oncol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"e014626","DOI":"10.1136\/bmjopen-2016-014626","article-title":"Organised screening for cervical cancer in France: a cost-effectiveness assessment.","volume":"7","author":"Barr\u00e9","year":"2017","journal-title":"BMJ Open"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer.","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/0003-4819-138-1-200301070-00012-w1","article-title":"The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.","volume":"138","author":"Bossuyt","year":"2003","journal-title":"Ann Intern Med"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"e1002388","DOI":"10.1371\/journal.pmed.1002388","article-title":"Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial.","volume":"14","author":"Canfell","year":"2017","journal-title":"Plos Med"},{"key":"R16-20250527","first-page":"424","article-title":"Evolution of human papillomavirus vaccination coverage in France - 2008-2018.","author":"Fonteneau","year":"2019","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"R17-20250527","first-page":"417","article-title":"Cervical cancer screening coverage in France, 2012-2017.","author":"Hamers","year":"2019","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CEJ.0000000000000365","article-title":"Population-based organized cervical cancer screening pilot program in France.","volume":"27","author":"Hamers","year":"2018","journal-title":"Eur J Cancer Prev"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ejca.2007.12.015","article-title":"Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s.","volume":"44","author":"Karim-Kos","year":"2008","journal-title":"Eur J Cancer"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","article-title":"HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.","volume":"10","author":"Kitchener","year":"2009","journal-title":"Lancet Oncol"},{"key":"R26-20250527","first-page":"CD008587","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population.","volume":"8","author":"Koliopoulos","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2468-2667(17)30007-5","article-title":"Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.","volume":"2","author":"Lew","year":"2017","journal-title":"Lancet Public Health"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/jech.56.6.461","article-title":"Hysterectomy and socioeconomic position in Rome, Italy.","volume":"56","author":"Materia","year":"2002","journal-title":"J Epidemiol Community Health"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.","volume":"26","author":"Maver","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"R37-20250527","article-title":"Arr\u00eat\u00e9 du 30 juillet 2020 modifiant l\u2019arr\u00eat\u00e9 du 29 septembre 2006 relatif aux programmes de d\u00e9pistage organis\u00e9 des cancers et relatif a` l\u2019organisation du d\u00e9pistage organis\u00e9 du cancer du col de l\u2019ut\u00e9rus. Journal officiel de la r\u00e9publique fran\u00e7aise. 15 ao\u00fbt 2020. n\u00b0 0200."},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"R32-20250527","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer.","volume":"357","author":"Naucler","year":"2007","journal-title":"N Engl J Med"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial.","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004347-199304000-00018","article-title":"Natural history of cervical intraepithelial neoplasia: a critical review.","volume":"12","author":"Ost\u00f6r","year":"1993","journal-title":"Int J Gynecol Pathol"},{"key":"R38-20250527","first-page":"1","article-title":"The impact of the COVID-19 pandemic on cancer care.","author":"Richards","year":"2020","journal-title":"Nat Cancer"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":"Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer.","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of cotesting in cervical screening.","volume":"110","author":"Schiffman","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2015.07.006","article-title":"Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials.","volume":"51","author":"Verdoodt","year":"2015","journal-title":"Eur J Cancer"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination.","volume":"1","author":"von Karsa","year":"2015","journal-title":"Papillomavirus Res"},{"issue":"Suppl 1","key":"R48-20250527","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening.","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J Clin Virol"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-3-25","article-title":"The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.","volume":"3","author":"Whiting","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:06:17Z","timestamp":1748361977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000701","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}